Mumbai, April 28 -- The agency has also affirmed the company's short term rating at '[ICRA] A1+'.

ICRA stated that the rating action factors in Indraprastha Medical Corporation Limited (IMCL)'s established presence and strong market position in the NCR region, its healthy operating metrics and its robust financial profile.

The ratings also factor in IMCL's revenue diversification across specialities, including oncology, neurology, cardiology and nephrology, among others.

The financial risk profile remains comfortable as reflected by minimal gearing, robust debt protection indicators and a strong liquidity profile.

Further, the ratings factor in the strong parentage of Apollo Hospitals Enterprise Limited (AHEL) along with its promoters...